These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26296048)

  • 21. Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update.
    Cappellari M; Bovi P
    Thromb Haemost; 2015 Aug; 114(2):440-4. PubMed ID: 25809649
    [No Abstract]   [Full Text] [Related]  

  • 22. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
    Fontaine GV; Mathews KD; Woller SC; Stevens SM; Lloyd JF; Evans RS
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):665-72. PubMed ID: 24875781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].
    Elikowski W; Małek M; Skowroński M; Wróblewski D; Skrzywanek P; Zawilska K
    Pol Merkur Lekarski; 2015 Oct; 39(232):227-30. PubMed ID: 26608490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
    Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
    Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolated hemopericardium associated with rivaroxaban: first case report.
    Shivamurthy P; Brar N; Therrien ML
    Pharmacotherapy; 2014 Sep; 34(9):e169-72. PubMed ID: 25074401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fatal intracranial haemorrhage in a hypertensive patient with atrial fibrillation and coronavirus disease 2019.
    Krzystanek E; Gawryluk J; Arkuszewski M
    Neuroradiol J; 2021 Apr; 34(2):147-150. PubMed ID: 33307996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Albumin and bleed risk in rivaroxaban treated patients.
    Wojakowski E; Cheruvil C; Hassan A; Holsen MR; Chen L; Rossi M; Wilcox N; Woodruff AE
    J Thromb Thrombolysis; 2020 Nov; 50(4):1004-1011. PubMed ID: 32279215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous thrombolysis for acute ischemic stroke in a patient receiving rivaroxaban.
    Landais A; Ginoux C
    J Stroke Cerebrovasc Dis; 2015 Mar; 24(3):e73-4. PubMed ID: 25561312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban and retropharyngeal haemorrhage.
    McCarter JA; Bell PR; McCadden L; Scally C
    BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26884072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RECURRENT SUBRETINAL HEMORRHAGE ASSOCIATED WITH RIVAROXABAN ANTICOAGULATION.
    Boyce MR; Barth BE; Singh A
    Retin Cases Brief Rep; 2016; 10(1):86-8. PubMed ID: 26196651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban.
    Comuth W; Christiansen JJ; Bloch-Münster AM; Husted S
    Blood Coagul Fibrinolysis; 2017 Jan; 28(1):102-104. PubMed ID: 26919451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rivaroxaban-Induced Gastrointestinal Bleeding Presenting as Acute Colon Obstruction.
    Cohen M; Nevo H; Hershko D; Becker A
    Pharmacology; 2017; 99(3-4):124-127. PubMed ID: 27988509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.